KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Net Income: 2019-2024

Historic Net Income for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$162.9 million.

  • AbCellera Biologics' Net Income fell 57.73% to -$47.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 192.35%. This contributed to the annual value of -$162.9 million for FY2024, which is 11.24% down from last year.
  • According to the latest figures from FY2024, AbCellera Biologics' Net Income is -$162.9 million, which was down 11.24% from -$146.4 million recorded in FY2023.
  • AbCellera Biologics' Net Income's 5-year high stood at $158.5 million during FY2022, with a 5-year trough of -$162.9 million in FY2024.
  • For the 3-year period, AbCellera Biologics' Net Income averaged around -$50.2 million, with its median value being -$146.4 million (2023).
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 5,715.65% in 2020, then crashed by 192.35% in 2023.
  • Over the past 5 years, AbCellera Biologics' Net Income (Yearly) stood at $124.2 million in 2020, then grew by 23.60% to $153.5 million in 2021, then climbed by 3.29% to $158.5 million in 2022, then plummeted by 192.35% to -$146.4 million in 2023, then declined by 11.24% to -$162.9 million in 2024.